Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Accumulated Expenses (2020 - 2024)

Pulmonx (LUNG) has disclosed Accumulated Expenses for 5 consecutive years, with $16.5 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Expenses rose 1.47% to $16.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was $16.5 million, a 1.47% increase, with the full-year FY2024 number at $16.5 million, up 1.47% from a year prior.
  • Accumulated Expenses was $16.5 million for Q4 2024 at Pulmonx, up from $16.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $16.5 million in Q4 2024 to a low of $8.7 million in Q4 2020.
  • A 5-year average of $12.6 million and a median of $13.3 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 54.5% in 2021, then decreased 2.21% in 2023.
  • Pulmonx's Accumulated Expenses stood at $8.7 million in 2020, then soared by 54.5% to $13.4 million in 2021, then decreased by 0.67% to $13.3 million in 2022, then rose by 22.28% to $16.2 million in 2023, then grew by 1.47% to $16.5 million in 2024.
  • Per Business Quant, the three most recent readings for LUNG's Accumulated Expenses are $16.5 million (Q4 2024), $16.2 million (Q4 2023), and $13.6 million (Q2 2023).